Pharmacokinetics of Antituberculosis Drugs in Plasma and Cerebrospinal Fluid in a Patient with Pre-Extensive Drug Resistant Tuberculosis Meningitis

References

• Furin J, Cox H, Pai M. Tuberculosis. Lancet. 2019;393(10181):1642–1656. doi:10.1016/S0140-6736(19)30308-3
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report. Switzerland: World Health Organization; 2021.
   Google Scholar
• Donovan J, Thwaites GE, Huynh J. Tuberculous meningitis: where to from here? Curr Opin Infect Dis. 2020;33(3):259–266. doi:10.1097/QCO.0000000000000648
   PubMed Web of Science ®Google Scholar
• Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more questions, still too few answers. Lancet Neurol. 2013;12(10):999–1010. doi:10.1016/S1474-4422(13)70168-6
   PubMed Web of Science ®Google Scholar
• du Preez K, Seddon JA, Schaaf HS, et al. Global shortages of BCG vaccine and tuberculous meningitis in children. Lancet Glob Health. 2019;7(1):e28–e9. doi:10.1016/S2214-109X(18)30474-1
   PubMed Web of Science ®Google Scholar
• Cecchini D, Ambrosioni J, Brezzo C, et al. Tuberculous meningitis in HIV-infected and non-infected patients: comparison of cerebrospinal fluid findings. Int J Tuberc Lung Dis. 2009;13(2):269–271.
   PubMed Web of Science ®Google Scholar
• Thwaites GE, Duc Bang N, Huy Dung N, Thi Quy H. The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with Tuberculous meningitis. J Infect Dis. 2005;192(12):2134–2141. doi:10.1086/498220
   PubMed Web of Science ®Google Scholar
• Soria J, Metcalf T, Mori N, et al. Mortality in hospitalized patients with tuberculous meningitis. BMC Infect Dis. 2019;19(1):9. doi:10.1186/s12879-018-3633-4
   PubMedGoogle Scholar
• Davis AG, Rohlwink UK, Proust A, Figaji AA, Wilkinson RJ. The pathogenesis of tuberculous meningitis. J Leukoc Biol. 2019;105(2):267–280. doi:10.1002/JLB.MR0318-102R
   PubMed Web of Science ®Google Scholar
• Wilkinson RJ, Rohlwink U, Misra UK, et al. Tuberculous meningitis. Nat Rev Neurol. 2017;13(10):581–598. doi:10.1038/nrneurol.2017.120
   PubMed Web of Science ®Google Scholar
• Nataprawira HM, Gafar F, Risan NA, et al. Treatment Outcomes of Childhood Tuberculous Meningitis in a Real-World Retrospective Cohort, Bandung, Indonesia. Emerg Infect Dis. 2022;28(3):660–671. doi:10.3201/eid2803.212230
   PubMed Web of Science ®Google Scholar
• Thwaites GE, Lan NT, Dung NH, et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis. 2005;192(1):79–88. doi:10.1086/430616
   PubMed Web of Science ®Google Scholar
• Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351(17):1741–1751. doi:10.1056/NEJMoa040573
   PubMed Web of Science ®Google Scholar
• Seddon JA, Visser DH, Bartens M, et al. Impact of drug resistance on clinical outcome in children with tuberculous meningitis. Pediatr Infect Dis J. 2012;31(7):711–716. doi:10.1097/INF.0b013e318253acf8
   PubMed Web of Science ®Google Scholar
• Upton CM, Steele CI, Maartens G, Diacon AH, Wiesner L, Dooley KE. Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB). J Antimicrob Chemother. 2022;77(6):1720–1724. doi:10.1093/jac/dkac067
   PubMed Web of Science ®Google Scholar
• Kempker RR, Smith AGC, Avaliani T, et al. Cycloserine and Linezolid for Tuberculosis Meningitis: pharmacokinetic Evidence of Potential Usefulness. Clin Infect Dis. 2021;72(7):1244–1246. doi:10.1093/cid/ciaa877
   PubMedGoogle Scholar
• Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis. 2010;90(5):279–292. doi:10.1016/j.tube.2010.07.002
   PubMed Web of Science ®Google Scholar
• Chambers E, Wagrowski-Diehl DM, Lu Z, Mazzeo JR. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852(1–2):22–34. doi:10.1016/j.jchromb.2006.12.030
   PubMed Web of Science ®Google Scholar
• Jang M, Kim J, Han I, Yang W. Simultaneous determination of LSD and 2-oxo-3-hydroxy LSD in hair and urine by LC-MS/MS and its application to forensic cases. J Pharm Biomed Anal. 2015;115:138–143. doi:10.1016/j.jpba.2015.07.001
   PubMed Web of Science ®Google Scholar
• Yamada K, Watanabe A, Takeshita H, Matsumoto KI. A method for quantification of serum tenascin-X by nano-LC/MS/MS. Clin Chim Acta. 2016;459:94–100. doi:10.1016/j.cca.2016.05.022
   PubMed Web of Science ®Google Scholar
• Marais S, Pepper DJ, Schutz C, Wilkinson RJ, Meintjes G. Presentation and outcome of tuberculous meningitis in a high HIV prevalence setting. PLoS One. 2011;6(5):e20077. doi:10.1371/journal.pone.0020077
   PubMed Web of Science ®Google Scholar
• Chin JH. Xpert MTB/RIF Ultra: the long-awaited game changer for tuberculous meningitis? Eur Respir J. 2017;50(4):1701201. doi:10.1183/13993003.01201-2017
   PubMed Web of Science ®Google Scholar
• Cresswell FV, Ssebambulidde K, Grint D, et al. High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a Phase II open-label randomised controlled trial (the RifT study). Wellcome Open Res. 2018;3:83. doi:10.12688/wellcomeopenres.14691.1
   PubMedGoogle Scholar
• George T, Moorthy RK, Rajshekhar V. Long tunnel external ventricular drain: an adjunct in the management of patients with infection associated hydrocephalus. Br J Neurosurg. 2019;33(6):659–663. doi:10.1080/02688697.2019.1667483
   PubMed Web of Science ®Google Scholar
• Zhou YJ, Wu JN, Chen LJ, Zhao HY. Comparison of infection rate with tunneled vs standard external ventricular drainage: a prospective, randomized controlled trial. Clin Neurol Neurosurg. 2019;184:105416. doi:10.1016/j.clineuro.2019.105416
   PubMed Web of Science ®Google Scholar
• WHO Guidelines Approved by the Guidelines Review Committee. WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment - Drug-Resistant Tuberculosis Treatment. Geneva: World Health Organization; 2020.
   Google Scholar
• DeVincenzo JP, Berning SE, Peloquin CA, Husson RN. Multidrug-resistant tuberculosis meningitis: clinical problems and concentrations of second-line antituberculous medications. Ann Pharmacother. 1999;33(11):1184–1188. doi:10.1345/aph.19008
   PubMed Web of Science ®Google Scholar
• Baron H, Epstein IG, Mulinos MG, Nair KG. Absorption, distribution, and excretion of cycloserine in man. Antibiot Annu. 1955;3:136–140.
   PubMedGoogle Scholar
• Ruslami R, Gafar F, Yunivita V, et al. Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis. Arch Dis Child. 2022;107(1):70–77. doi:10.1136/archdischild-2020-321426
   PubMed Web of Science ®Google Scholar
• Märtson AG, Burch G, Ghimire S, Alffenaar JC, Peloquin CA. Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems. Expert Opin Drug Metab Toxicol. 2021;17(1):23–39. doi:10.1080/17425255.2021.1836158
   PubMed Web of Science ®Google Scholar
• Rapid Communication: key Changes to Treatment of Multidrug- and RifampicinResistant Tuberculosis (MDR/RR-TB): world Health Organization. Available from: https://www.who.int/tb/publications/2019/WHO_RapidCommunicationMDRTB2019.pdf?ua=1. Accessed March 8, 2023.
   Google Scholar
• Luque S, Grau S, Alvarez-Lerma F, et al. Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections. Int J Antimicrob Agents. 2014;44(5):409–415. doi:10.1016/j.ijantimicag.2014.07.001
   PubMed Web of Science ®Google Scholar
• Cabrera-Maqueda JM, Fuentes Rumí L, Valero López G, et al. Difusión de los antibióticos en el sistema nervioso central [Antibiotic diffusion to central nervous system]. Rev Esp Quimioter. 2018;31(1):1–12. doi:10.1007/s10096-017-2973-0. Spanish.
   PubMed Web of Science ®Google Scholar
• Sullins AK, Abdel-Rahman SM. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatr Drugs. 2013;15(2):93–117. doi:10.1007/s40272-013-0017-5
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother. 1997;41(12):2670–2679. doi:10.1128/AAC.41.12.2670
   PubMed Web of Science ®Google Scholar
• Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23(4):858–883. doi:10.1128/CMR.00007-10
   PubMed Web of Science ®Google Scholar
• De Lange EC, Hammarlund-Udenaes M. Translational aspects of blood-brain barrier transport and central nervous system effects of drugs: from discovery to patients. Clin Pharmacol Ther. 2015;97(4):380–394. doi:10.1002/cpt.76
   PubMed Web of Science ®Google Scholar
• Te Brake LHM, de Knegt GJ, de Steenwinkel JE, et al. The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: unraveling the Black Box. Annu Rev Pharmacol Toxicol. 2018;58:271–291. doi:10.1146/annurev-pharmtox-010617-052438
   PubMed Web of Science ®Google Scholar
• Tucker EW, Guglieri-Lopez B, Ordonez AA, et al. Noninvasive (11) C-rifampinpositron emission tomography reveals drug biodistribution in tuberculous meningitis. Sci Transl Med. 2018;10:470. doi:10.1126/scitranslmed.aau0965
   Web of Science ®Google Scholar